RxDoctor Payments Data

Sarah Gambridge

Family · Mc Murray, PANPI 1538538111

Payments from drug & device makers

$8,321in general payments, 2019–2025

Across 458 payments — averaging $18.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$1K
  • GSK$1K
  • Lilly USA, LLC$670
  • Novo Nordisk$639
  • Abbott$381
  • plus $2K from 40 others

What the payments were for

  • Food & beverage$8,321100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,321 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$29,842
Medicare patients
153
Services billed
868

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin131$138,221
EliquisApixaban104$108,355
OzempicSemaglutide60$60,948
XareltoRivaroxaban52$51,271
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$21,816
JanuviaSitagliptin Phosphate25$18,566
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr38$18,509
TrulicityDulaglutide14$15,050
MyrbetriqMirabegron19$14,483
SynthroidLevothyroxine Sodium140$10,531
FarxigaDapagliflozin Propanediol19$9,875
LinzessLinaclotide14$7,194
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$7,008
Atorvastatin Calcium599$4,620
Incruse ElliptaUmeclidinium Bromide12$4,178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$184$138,221131 claims
PfizerEliquis$1,300$108,355104 claims
Novo NordiskOzempic$639$60,94860 claims
Johnson & JohnsonXarelto$55$51,27152 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta$1,098$44,50475 claims
MerckJanuvia$84$18,56625 claims
AbbVieSynthroid, Linzess$1,866$17,725154 claims
Lilly USA, LLCTrulicity$670$15,05014 claims
Astellas Pharma US IncMyrbetriq$151$14,48319 claims
AstraZenecaFarxiga$273$9,87519 claims
Sanofi-aventis U.S. LLCLantus$28$1,21712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.

Other family in Mc Murray

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →